Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours SunRock Biopharma S.L. ("SunRock"), a biopharmaceutical company that is developing a portfolio
Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein Ellipses Pharma granted exclusive global rights to develop and commercialise SRB22, in solid tumours LONDON and SANTIAGO DE COMPOSTELA, Spain, May 25, 2022: SunRock Biopharma S.
22 febbraio 2021 10:13
Fonte: Adnkronos
#salute-e-benessere
NANJING, China, Feb. 22, 2021 /PRNewswire/ On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning preclinical discovery to large scale GMP manufacturing for SunRock s CCR9 therapeutic antibody candidates. GenScript ProBio will provide SunRock Biopharma a one-stop-solution from antibody discovery, cell line development, process development to GMP drug substance and drug product manufacturing services.
By leveraging complementary strengths and capabilities, the parties are committed to the R&D, manufacturing process development, NMPA, FDA & EMA IND filings of CCR9 therapeutic antibodies, towards rapid development of novel antibody therapeutics.
(1)
NANJING, China, Feb. 22, 2021 /PRNewswire/ On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning preclinical discovery to large scale GMP manufacturing for SunRock s CCR9 therapeutic antibody candidates. GenScript ProBio will provide SunRock Biopharma a one-stop-solution from antibody discovery, cell line development, process development to GMP drug substance and drug product manufacturing services.
By leveraging complementary strengths and capabilities, the parties are committed to the R&D, manufacturing process development, NMPA, FDA & EMA IND filings of CCR9 therapeutic antibodies, towards rapid development of novel antibody therapeutics.
CCR9 is a novel therapeutic target expressed in highly aggressive cancer. It is associated with increased metastatic potential and tumor-chemoresistance. This program will enable new treatment formats with innovative